Johan ET van Hylckama Vlieg's research while affiliated with Kaleido Biosciences and other places

What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (3)

Modulation of the Gut Microbiome by Novel Synthetic Glycans for the Production of Propionate and the Reduction of Cardiometabolic Risk Factors
Preprint
Full-text available
  • Apr 2022
Background Increasing evidence indicates that an altered gut microbiome participates in the development of cardiometabolic syndrome and associated risk factors, such as insulin resistance, dyslipidemia, and obesity, and that targeting the gut microbiome is a promising strategy to lower the risk for cardiometabolic diseases. Part of this reduction i...
Cite
Download full-text
Synthetic glycans that control gut microbiome structure mitigate colitis in mice
Preprint
Full-text available
  • Jan 2022
Relative abundances of bacterial species in the gut microbiome have been linked to many diseases. Species of gut bacteria are ecologically differentiated by their abilities to metabolize different glycans, making glycan delivery a powerful way to alter the microbiome to promote health. We describe the properties and therapeutic potential of chemica...
Cite
Download full-text
1208. Development of a Novel Synthetic Glycan to Prevent Bacterial Infections and Ameliorate Respiratory Viral Infections
Article
Full-text available
  • Dec 2020
Background The prevention and treatment of bacterial infections is a human health challenge. A disadvantage of antibiotics is that they often kill beneficial commensal, bacteria in addition to, pathogenic bacteria. Indiscriminate killing disrupts the homeostasis between commensal bacteria and the host gut epithelium allowing colonization of the gut...
Cite
Download full-text

Citations

... 12 KB109, a novel synthetic glycan developed by Kaleido Biosciences, Inc, has been shown to increase SCFA production compared with a negative control in ex vivo studies, and importantly shows a consistent response across multiple healthy donor fecal communities. 22 KB109 is related to a class of compounds that is generally recognized as safe (GRAS) or determined to be GRAS based on history of safe human exposure. This class is commonly accepted by regulators as safey for use in food and enables rapid advancement into human clinical studies. ...
Reference: Targeting the Microbiome With KB109 in Outpatients with Mild to Moderate COVID-19 Reduced Medically Attended Acute Care Visits and Improved Symptom Duration in Patients With Comorbidities [preprint]
View full-text